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KESAN PROPOLIS KELULUT KEPADA TEKANAN OKSIDATIF DAN
INTEGRITI STRUKTUR JANTUNG KE ATAS TIKUS DIABETES
TERARUH STREPTOZOTOSIN
ABSTRAK
Penyakit  Diabetes mellitus (DM) merupakan penyakit tidak berjangkit yang
sangat membimbangkan disebabkan impak sosio-ekonomi yang besar ke atas negara
terutamanya  Malaysia  di  mana  prevalens  mengatasi  angka  global.  T1DM adalah
sejenis penyakit metabolik kronik yang bercirikan hiperglisemia yang berterusan dan
penghasilan  tekanan  oksidatif  yang  berlebihan  yang  menyebabkan  diabetik
kardiomiopati.  Propolis  kelulut  dihasilkan  daripada  sebatian  resin  daripada  getah
pokok dan saliva kelutut yang kaya dengan kompaun fenolik. Ia mempunyai potensi
sebagai antihiperglisemia,  antioksida dan  antiiskemia.  Namun  demikian,  tiada
penyelidikan terdahulu yang melaporkan kesan pengambilan propolis kelulut ke atas
jantung  pesakit  DM.  Jadi,  kajian  ini  bertujuan  untuk  mengkaji kesan  rawatan
propolis kelulut terhadap stres oksidatif dan histopatologi jantung tikus DM aruhan
streptozotocin.  Sebatian  polar  diekstrak  daripada  propolis  kelulut  mentah  melalui
kaedah pengekstrakan etanol. Tikus jantan Sprague Dawley dibahagikan kepada lima
kumpulan (n=8) iaitu  normoglisemia  (non-DM),  diabetes  tanpa  rawatan  (DM),
diabetik  dirawat  dengan  300  mg/kg/day  metformin  (DM+Metformin),  diabetik
dirawat dengan 300 mg/kg/day propolis (DM+Propolis) dan diabetik dirawat dengan
300  mg/kg/day  metformin  dan  300  mg/kg/day  propolis  (DM+Combined) dan
rawatan  diberi  sekali  sehari.  Satu  dos  mengandungi  60mg/kg  streptozotocin
diberikan melalui suntikan intraperitoneal untuk mengaruh DM jenis satu. Rawatan
xxii
diberi  melalui  gavaj oral  selepas aruhan DM berjaya.  Berat badan, glukosa darah
semasa puasa, pengambilan air dan pengambilan makanan diambil setiap minggu.
Selepas  empat  minggu,  tikus  akan  dimatikan  dengan  300  mg/kg  sodium
pentobarbital.  Serum  darah  dan  jantung dikumpul  untuk  menganalisis  asai
kalorimetri (penanda stres oksidatif dan enzim antioksidan) dan histopatologi. Tikus
DM  mengalami  polidipsia,  polifagia  dan  penyusutan berat badan  disebabkan
hiperglisemia.  Jantung  tikus  DM  menunjukkan  perubahan  ciri-ciri  diabetik
kardiomiopati  seperti  hipertrofi  kardiomiosit,  fibrosis  dan  fibrosis  perivaskular.
Pengambilan  metformin  atau  propolis  melindungi histopatologi  dan  perubahan
biokimia  yang  berlaku  semasa  diabetik  kardiomiopati.  Gabungan  metformin  dan
propolis  juga  menampakkan  perubahan  yang  baik  berbanding  dengan  metformin
sahaja.  Natijahnya,  kajian  mengenai propolis  kelulut  ini boleh memberikan hasil
positif  ke  atas tikus diabetik  kardiomiopati  melalui  sifat  antihiperglisemia  dan
antioksidatif yang dikandungnya.
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EFFECTS OF STINGLESS BEE PROPOLIS ON OXIDATIVE STRESS AND
STRUCTURAL INTEGRITY OF HEART IN STREPTOZOTOCIN-
INDUCED DIABETIC RATS
ABSTRACT
Diabetes mellitus is a concerning non-communicable disease worldwide that
has great socio-economic impact especially in Malaysia where the prevalence beats
global figure. Type 1 diabetes mellitus is a chronic metabolic disorder characterised
by  persistent  hyperglycaemia  leading  to  overproduction  of  oxidative  stress  that
causes  diabetic  cardiomyopathy.  Stingless  bee  propolis  is  rich  in  phenolic
compounds that is  made of resins from plant exudates and stingless bee’s saliva. It
has antihyperglycaemia,  antioxidative and antiischemic potential.  Nevertheless, no
previous study reported the effect of stingless bee propolis on diabetic heart. Thus,
this study aims to determine the effect of supplementation of stingless bee propolis
on oxidative  stress  and histopathology of heart  in  streptozotocin-induced diabetic
rats.  The  polar  antioxidative  compounds  was  extracted  from  raw  stingless  bee
propolis using ethanolic extract. Adult male  Sprague Dawley  rats was divided into
five  groups (n=8):  normoglycaemia  (non-DM),  untreated  diabetes  mellitus  (DM),
diabetic treated with 300 mg/kg/day metformin (DM+Metformin),  diabetic treated
with  300  mg/kg/day  propolis  (DM+Propolis),  diabetic  treated  with  both  300
mg/kg/day metformin and 300 mg/kg/day propolis (DM+Combined) and treatment
was given on daily basis. Single dose of 60mg/kg streptozotocin was administered
intraperitoneally to induce type 1 diabetes mellitus. Treatment was given for four
weeks duration following successful induction of diabetes mellitus via oral gavage.
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Body weight, fasting blood glucose, water intake and food intake were taken every
week.  The  rats  were  sacrificed  after  four  weeks  using  300  mg/kg  of  sodium
pentobarbital.  Serum and heart  were collected  for  determination  of  colourimetric
assays  (oxidative  stress  markers  and  antioxidative  enzymes)  and  histopathology.
Diabetic  rats  experienced  manifestation  of  hyperglycaemia  such  as  polydipsia,
polyphagia and weight loss. Their heart contains higher oxidative stress markers and
alteration in antioxidative enzymes. Heart of diabetes mellitus rats showed features
of diabetic  cardiomyopathy including cardiomyocyte hypertrophy,  cardiac  fibrosis
and  perivascular  fibrosis.  Metformin  or  propolis  supplementation  reversed  the
clinical manifestation of diabetic mellitus but propolis alleviated histopathology and
biochemical alteration of diabetic cardiomyopathy better than metformin. However,
combination  of  metformin  and  propolis  supplementation  observed  better
improvement than metformin alone. In a nutshell, this study of stingless bee propolis
managed to produce positive  data  on diabetic  cardiomyopathy in  rats  through its




1.1 A Concerning Global Health Threat: Non-communicable Diseases
Amid era of globalisation, the life expectancy of population increased worldwide.
From 1950 to 2017, life expectancy of men increased from 48.1 years to 70.5 years,
whereas  life  expectancy  of  women  gained  from  52.9  years  to  75.6  years.  The
improvement  of life  expectancy means greater  emphasis  on health  care  sector  to
provide  sustainable  health  care  goals.  Researchers  from  the  Institute  for  Health
Metrics and Evaluation (IHME) came out with a systematic analysis for the global
burden of disease study 2017. The statistic was very concerning. Non-communicable
diseases occupied the base of the pyramid in worldwide mortality,  accounting for
73.4% death in 2017. For just 10 years (2007-2017), they saw an increased of 22.7%
deaths  from  non-communicable  diseases,  which  translated to  an  additional  7.61
million  deaths.  The  predicted  percentage  of  mortality  from  non-communicable
diseases  was bound to climb in the future as the other causes of mortality such as
communicable,  maternal,  neonatal  and  nutritional  causes  and  accidental  death
decrease over time (Roth et al., 2018) 
1.2 A Silent Killer: Diabetes Mellitus
According  to  World  Health  Statistic  2018,  the  top  four  contributors  to  non-
communicable  disease  mortality  include  cardiovascular  disease  with  17.9  million
deaths (44%), cancer with 9.0 million deaths (22%), chronic respiratory disease with
3.8 million deaths (9%) and diabetes mellitus with 1.6 million deaths (4%) (World
Health Organization, 2018). Although diabetes mellitus accounts for only 4% of non-
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communicable diseases mortality, it should not be overlooked. In Framingham study,
diabetes  mellitus  was  implicated  as  precursor  of  mortality  and  morbidity  in
cardiovascular diseases, subsequently listed as major risk factor for cardiovascular
diseases  (Kannel and McGee, 1979). Furthermore, a series of meta-analyses show
that  diabetes  mellitus  increased risk  of  cancers  such  as  colorectal  cancer,  breast
cancer, liver cancer, pancreatic cancer, bladder cancer and non-Hodgkin lymphoma
(Vigneri et al., 2009). 
1.3 Landscape of Diabetes Mellitus in the World and Malaysia
Diabetes  mellitus  is  a  complex  metabolic  disorder  characterised  by  presence  of
persistent  hyperglycemia  due  to  defects  in  insulin  secretion,  defective  insulin
activity,  insulin  resistance  or  both  (American  Diabetes  Association,  2017).  The
diagnosis  of  diabetes  mellitus  is  by  the  presence  of  clinical  symptoms  such  as
polyuria, polydipsia or thirst, together with laboratory tests such as fasting plasma
glucose  ≥7.0  mmol/L  or  2-hour  plasma  glucose  ≥11.1  mmol/L  or  glycated
haemoglobin A1c (HbA1c) >6.5 %. In the absence of clinical symptoms, repeated
abnormal  laboratory  result  is  required  to  warrant  diagnosis  of  diabetes  mellitus
(Clinical Practice Guideline Malaysia, 2015; Goldenberg and Punthakee, 2013).
Diabetes mellitus is a heterogenous disease and pathogenesis is not fully understood.
However, studies identified several risk factors to diabetes mellitus. The risk factors
for diabetes mellitus include modifiable and non-modifiable risk factors. The non-
modifiable factors are family history of diabetes mellitus and ethnicity such as Asian,
Hispanics and African American (Meigs et al., 2000; Shai et al., 2006). Modifiable
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factors are obesity, lack of exercise, smoking and unhealthy diet (Menke et al., 2014;
Reis et al., 2011).
Diabetes mellitus poses a major health threat worldwide, despite numerous measures
to tackle this  problem. The data  from International  Diabetes Federation (IDF) on
global prevalence of diabetes mellitus is alarming, with estimated prevalence to rise
in the coming years. The prevalence of diabetes mellitus is 151 million in 2000, 285
million in 2009 and 451 million in 2017 (1 in 11 adults)(Cho et al., 2018). This will
lead to a huge global economic burden, with expenditure of USD 1.3 trillion in 2015
and expected  a  substantial  increase  to  USD 2.1 trillion  in  2030  (Bommer  et  al.,
2018).  The situation of diabetes mellitus in Malaysia is worse compared to global
figure,  one  in  five  Malaysian  adults  has  diabetes  mellitus.  Therefore,  the  health
expenditure  to  manage  diabetes  and it’s  complication  will  be  costlier  to  manage
(Kadir Abu Bakar et al., 2015).
1.4 Cardiovascular Disease as a Major Complication of Diabetes Mellitus
Complications  that  arise  from diabetes  mellitus  are  common and responsible  for
significant morbidity and mortality. It is broadly categorised as microvascular and
macrovascular  complications  with  microvascular  complication  predominating  the
picture.  Microvascular  diseases  are  nephropathy,  neuropathy  and  retinopathy,
whereas macrovascular diseases include cardiovascular diseases  (Papatheodorou et
al., 2018). 
Cardiovascular diseases (CVD) are the number one killer worldwide and Malaysia is
not spared.  Since early 1980s, Malaysia has been plagued with health issue from
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cardiovascular diseases. The trend kept increasing over time and caught the attention
of ministry of health of Malaysia. In 2010, National Strategic Plan was initiated to
combat  non-communicable  diseases  especially  cardiovascular  diseases.  Integrated
approach  is  the  missing  puzzle.  The  collaboration  from dietitian  to  clinicians  is
required  to  tackle  this  seemingly  uncontrollable  situation  (Clinical Practice
Guidelines, 2017). 
Cardiovascular diseases include two major categories which are vascular and heart
diseases. Examples of vascular diseases are coronary artery disease, cerebrovascular
disease, peripheral vascular disease and disease of aorta. Congenital heart disease,
rheumatic heart disease, cardiomyopathy and cardiac arrhythmia are heart diseases
(Mendis et al., 2011). 
1.5 Cardiovascular Disease in Type 1 Diabetes Mellitus 
Type  1  diabetes  mellitus  is  an  autoimmune  disease  mediated  by  T-lymphocytes,
causing  destruction  in  β-cell  in  pancreatic  islets  of  Langerhans  leading  to
hyperglycemia  (American  Diabetes  Association.,  2014).  The  global  prevalence,
incidence  and  trend  of  type  1  diabetes  mellitus  varies  in  geographical  location
worldwide, rendering small epidemiological studies inaccurate. Several large youth
registry  studies  of  type  1  diabetes  mellitus  such  as  World  Health  Organization
Multinational Project for Childhood Diabetes (DIAMOND project) (Karvonen et al.,
2000),  EURODIAB study (Eurodiab  Ace Study Group,  2000)  and  SEARCH for
Diabetes  in  United  States  Youth  study  (SEARCH)   (Liese  et  al.,  2006).  Both
DIAMOND project and SEARCH study found out that highest prevalence of type 1
diabetes  mellitus  are  younger  age  groups  especially  10-14  years  old.  Regarding
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temporal  trends,  all  three  studies  reflected  a  rise  in  type  1  diabetes  mellitus.
DIAMOND,  EURODIAB and  SEARCH  studies  reported  2.8%,  2.3% and  3.4%
annual rise in type 1 diabetes mellitus respectively. The cause is still unknown to
researchers.  The  sparse  data  on  adult  type  1  diabetes  mellitus  impedes  further
research. However, type 1 diabetes mellitus is a lifelong condition, the rising number
of youths living with diabetes mellitus will  grow into adulthood as the treatment
improves.
When compared to type 2 diabetes mellitus, type 1 diabetes mellitus has less data on
cardiovascular  disease.  The  increment  of  cardiovascular  disease  risk  in  diabetes
mellitus  is  largely  derived  from  cohorts  of  type  2  diabetes  mellitus  or
undistinguished  diabetes  mellitus  subtypes.  Thus,  the  relation  of  type  1  diabetes
mellitus and cardiovascular disease needs further clarity  (De Ferranti et al., 2014).
There are two large observational studies which are Scottish Registry Linkage Study
(SRLS)  and  UK General  Practice  Research  Database  (GPRD)  that  demonstrated
higher rates of cardiovascular diseases in type 1 diabetes mellitus as compared to
general population  (Livingstone et al.,  2012; Soedamah-Muthu et al.,  2006). Both
studies reported large proportion of cardiovascular disease that derived from older
age group when compared to younger age group. When the glucose control is strictly
monitored and adhered in type 1 diabetes mellitus, the risk of cardiovascular disease
falls 42% as shown in a landmark Diabetes Control and Complications Trial (DCCT)
(Nathan et al., 2005). 
In  Malaysia,  Diabetes  in  Children  and  Adolescent  Registry  (DiCARE)  reported
69.2% of type 1 diabetes occurred in children and adolescents as opposed to 90%
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worldwide.  Majority  of  type  1  diabetes  mellitus  patients  presented  with  diabetic
ketoacidosis,  with  64.7%  recorded  in  Malaysia,  19.4% in  Finland,  26.3%  in
Germany. The proportion of diabetic ketoacidosis in Malaysia is increasing in trend,
implying poor awareness of glucose monitoring among public  (Hong et al., 2015).
Indeed, the glycaemic control of patients with type 1 diabetes mellitus in Malaysia
recorded HbA1c  of 9.46%, far from the optimal target of 7.5% (Lim et al., 2016).
Poor glycaemic control, HbA1c > 9% is associated with increased total cholesterol,
LDL cholesterol, triglyceride, reduced HDL cholesterol. Therefore, good glycaemic
control is important to minimise risk of cardiovascular disease  (Dobrovolskiene et
al., 2013).
Only a few studies have reported risk of cardiac failure in type 1 diabetes mellitus.
Swidish national diabetes registry found that incidence of cardiac failure is inversely
related  to  glycaemic  control.  Both type 1 and 2 diabetes  mellitus  both adversely
affect  heart  structure  and  function  but  the  mechanism  and  underlying
pathophysiology  differs  (Hölscher  et  al.,  2016).  Diastolic  dysfunction  is  more
common than systolic dysfunction in type 1 diabetes mellitus  (Patil  et al.,  2011).
However, several small-scale studies found no increased risk of heart failure in type
1 diabetes mellitus. It is noteworthy that patients in those studies are treated with
insulin and will  normalise  blood glucose that  attenuate  the detrimental  effects  of
metabolic derangement on heart (Hölscher et al., 2016).
1.6 Epidemiological Evidence of Diabetic Cardiomyopathy
Diabetes Mellitus is an atherogenic state leading to myocardial infarction and stroke.
It was strongly related to microvascular disease and macrovascular disease. Before
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1972, the increased cardiovascular mortality and morbidity in diabetic patients was
thought to be only due to vasculature disease. In 1972, Rubler did a postmortem on
four  diabetic  patients  with  congestive  cardiac  failure  in  the  absence  of  coronary,
hypertensive  or  valvular  heart  disease.  The  pathology  findings  of  heart  such  as
myocardial  hypertrophy,  fibrosis  and  perivascular  fibrosis  were  noted.  Rubler
proposed  a  type  of  cardiomyopathy  specific  to  diabetes  mellitus.  However,  his
opinion  was  refuted  on  few confounding  factors  surrounding study subjects.  For
instance, mitral regurgitation, anemia and renal insufficiency (Fein and Sonnenblick,
1985). 
In 1974, Framingham study over 18 years involving 5209 people to determine the
incidence  of  cardiac  failure  in  relation  to  diabetes  mellitus  was  published.
Interestingly, after adjustment for all the confounding variables such as age, blood
pressure, weight and serum cholesterol, diabetes mellitus patients have fourfold to
fivefold increased risk of congestive cardiac failure (Kannel et al., 1974). Since then,
multiple epidemiological studies support the concept of diabetic cardiomyopathy.
Diabetic cardiomyopathy can cause cardiac failure alone or accelerate cardiac failure
in  the  presence  of  additional  cardiac  complications  such  as  hypertension  and
coronary heart disease. A study done using ultrasound to screen diabetic patients for
diabetic  cardiomyopathy  found that  40-60% of  patients  suffered  some degree  of
diastolic dysfunction  (Sharma and McNeill,  2006). Despite the high mortality and
morbidity caused by diabetes-associated heart failure, the pathophysiology remains
understudied (Russo and Frangogiannis, 2016).
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1.7 Oxidative Hypothesis of Diabetic Cardiomyopathy 
Prolonged  hyperglycaemia  promotes  endogenous  non-enzymatic  formation  of
advanced glycation  end products (AGE) known as Millard reaction.  Receptor  for
AGE (RAGE)  is  a  multiligand  membrane  bound  receptor  from immunoglobulin
superfamily exhibited by numerous cell types. AGE can cross link membrane bound
RAGE and causes activation of wide array of pro-oxidative and pro-inflammatory
cascade,  leading to generation of  thiobarbituric acid reactive substances (TBARS)
and activation of oxidative stress-sensitive NF-κBB.  (Goldin et al., 2006).  There are
two  soluble  forms  of  RAGE  (sRAGE)  which  are  endogenous  secretory  RAGE
(esRAGE) and cleaved RAGE (cRAGE). esRAGE is formed by alternative splicing
of RAGE gene within a cell and secreted into plasma. Whereas cRAGE is produced
when metalloproteinases cleave the membrane bound RAGE. Both soluble variant of
RAGE can act as decoy receptor to RAGE ligand such as AGE, reducing RAGE
signaling (Daffu et al., 2013; Heier et al., 2015a; Tan et al., 2007).
Malondialdehyde  (MDA)  is  formed  from  peroxidation  of  lipids  (arachidonic,
eicosapentaenoic and docosahexaenoic acid) due to oxidants or oxidative stress and
accumulation  of  MDA in tissue and is  associated  with  complications  in  diabetes
mellitus  (Negre-Salvayre  et  al.,  2008).  MDA  classically  reacts  reversibly  and
irreversibly  to  protein  and  phospholipid  causing  profound  damaging  effect  in
cardiovascular  system.  In  diabetes  mellitus,  the  collagen  is  first  modified  by
glycation process leading to series of lipid peroxidation to MDA. MDA and AGE
both can form intermolecular cross link within protein and lipid. The damaging effect
can be prevented through antioxidant therapy (Slatter et al., 2000).
8
Superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx) are
first line antioxidative defense system in every cell that convert free radicals to stable
and harmless compounds. Superoxide ions and singlet oxygen radical produced in
cells will be converted to hydroxyl radical by SOD and then to water and oxygen by
both CAT and GPx. Decrease in antioxidative defense system will lead to buildup of
oxidative  stress  reflected  by  increased  lipid  peroxidation  (MDA)  (Ighodaro  and
Akinloye, 2018). In conclusion, disruption in metabolic and antioxidative function in
diabetes mellitus will increase oxidative stress, causing diabetic cardiomyopathy (Jia
et al., 2018).
1.8 Justification of Study
Natural products are rich in antioxidants such as polyphenols and flavonoids which
can protect against cardiovascular diseases (Jia et al., 2018). Phytochemical analysis
of  Malaysian  stingless  bee  propolis  reveals  flavonoids,  polyphenols,  terpenoids,
resins,  tannins,  saponins  and  xanthoproteins  (Nurhamizah  Ibrahim et  al.,  2016 ;
Usman  et  al.,  2016).  In  addition,  Malaysian  stingless  bee  propolis  confer
antihyperglycaemic, antiinflammatory, antioxidative and cardioprotective benefits. A
study of stingless  bee propolis  supplementation  on myocardial  infarcted  rats was
observed  to  improve antioxidant  enzymes in  cardiac tissue  (Ahmed et  al.,  2017).
However, the cardioprotective effect of Malaysian stingless bee propolis on diabetic
heart has not been reported. Thus, this study is aims to determine the bioactivity of
Malaysian stingless bee propolis specifically on diabetic cardiomyopathy.
Meliponiculture  is  seen  as  a  potential  area  for  Malaysia  to  achieve  high  income
nation.  Stingless beekeeping can generate  huge agricultural  income and relatively
safe  (Ismail.  M & Ismail.  W, 2018). World Health Organisation reported 50-80%
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population  of  developing  and  developed  countries  utilised traditional  and
complementary medicine (T&CM). In line with WHO traditional medicine strategy
2014-2023  (Qi, 2013) and Malaysia’s T&CM blueprint 2018-2027, the safety and
efficacy of any T&CM product should be proven by research. In addition, National
Key  Result  Areas  (NKRA)  and  National  Key  Economic  Area  (NKEA)  also
emphasised on self-sustainable agro-food industry together with food security and
food safety policy  (Bakar  et  al.,  2012).  Therefore,  current  study conforms to the




To determine the effects of stingless bee propolis on oxidative stress and structural
integrity of heart in streptozotocin-induced diabetic rats.
1.9.2 Specific Objectives
1) To determine the effect of stingless bee propolis on body weight, food and
water intake of diabetic rats. 
2) To determine the effect of stingless bee propolis on fasting blood glucose of
diabetic rats.
3) To investigate the effect of stingless bee propolis on oxidative stress marker
(MDA and AGE) and antioxidative defences (SOD, GPx, CAT, esRAGE) in
heart homogenate and serum esRAGE.
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4) To  evaluate  the  effect  of  stingless  bee  propolis  on  histomorphological
changes in heart of diabetic rats.
1.10 Research Hypothesis
Stingless  bee propolis  protects  diabetic  cardiomyopathy  of  streptozotocin-induced




2.1 Meliponiculture or Apiculture: The Battle of Sustainability in Malaysian
Beekeeping Industry
Meliponiculture  refers  to  beekeeping  with  stingless  bee  comprising  of  tribe
Meliponini (genus Melipona and Trigona), whereas apiculture is the beekeeping with
stinger  honeybee  (genus  Apis)  (Razali  et  al.,  2018).  Beekeeping  industry  will
continue  to  bloom globally,  with  honey as  the  main  production  and majority  of
honey originates from well-established apiculture. The honey from honey bee was
traditionally  regarded as  better  quality  than honey from stingless  bee,  the reason
being stingless bee honey contains higher water content favorable for fermentation
(Chidi and Odo, 2017). 
However, Malaysia apiculture was badly hit by colony collapsed disorder due to the
Varroa destructor parasite mite outbreak in 1996. The imported  Apis Mellifera bee
was infected and spread to other honey bee. Malaysia had observed plunging honey
production from 1996 to 2010 and it took nearly 14 years for the beekeeping industry
to recover.  In contrast,  the meliponiculture has expanded over the years,  without
major  disease  outbreak  within  the  stingless  bee  community  (Ismail,  2016). This
sparked researches on the ecology and behavior of stingless bees. 
According to Malaysian Agricultural Research and Development Institute (MARDI),
stingless  bees  with  small  and  dimunitive  figure  than  honeybee,  can  pollinate
numerous crops including small-sized flowers, therefore environment conservation
can be achieved. In addition, stingless bees are not chosey in forming a colony hive,
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giving  huge  space  for  manipulation  of  artificial  hive  without  jeopardising  their
ecology. Also, as the name implies, the stingless bees do not sting, so they poses no
danger  to  the  surroundings  and  make  extraction  of  honey,  pollen  and  propolis
relatively  easier  and safer.  Besides,  honeybees  often  lost  their  way back to  their
colony when foraging as compared to stingless bees. Furthermore, stingless bees are
more resistant to diseases from pests and parasites than honeybees (Chidi and Odo,
2017; Jalil et al., 2017). 
Despite numerous benefits of meliponiculture, there are setbacks to it. In Malaysia,
the production of stingless bee product is smaller per bee colony compared to honey
bee product. This can be attributed to limited knowledge of beekeeper about stingless
bees  (Jaffé  et  al.,  2015).  The lack  of knowledge also resulted in  meliponiculture
being less popular choice in beekeeping industry, stingless bee products with shorter
shelf  life  and  lower  quality  (Jalil  et  al.,  2017).  In  response,  Reinventing  Honey
Quality (RHQ) project was launched in 2012 to improve stingless beekeeping, with a
vision of achieving world class stingless bee honey industry by addressing all issues
surrounding meliponiculture  (Mustafa  et  al.,  2018).  In  sum,  stingless  beekeeping
industry is a holistic  approach to beekeeping in Malaysia which will  also benefit
socio-economies,  survival  of  stingless  bee  species  and  long-term  ecological
conservation and preservation. 
2.2 Biology of Stingless Bee
Stingless bees originate from Africa, then migrated to the north to Europe and North
America and subsequently to Asia. They adapt well to tropical countries. There are
nearly  500  species  of  stingless  bees  known  around  the  globe.  In  Malaysia,
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approximately  38  species  of  stingless  bees  identified,  but  only  four  species  are
involved  in  beekeeping  industry  including  Heterotrigona  itama,  Geniotrigona
thoracica, Lepidotrigona terminata and Tetragonula leviceps (Mustafa et al., 2018).
Out  of  the  four  species,  only  two  species  (Heterotrigona  itama,  Geniotrigona
thoracica) are most notable in Malaysia beekeeping industry  (Hassan et al., 2018).
Stingless bees had undergone evolutionary changes such as reduction in wing size
and sting. Their  flight range is shorter than honeybees,  around 0.3 to 2 km from
beehive depending on their size (Van Veen, 2014). 
The caste of stingless bee consists of male and female bees. The male bees are called
drones and their job is to mate with queen bees of other beehives. While female bees
can differentiate into nurse bees and then worker bees or queen bees. In a beehive,
the most nourished female bee will grow into queen bee. Others will differentiate
into  worker  bees.  Nurse  bee  are  young  worker  bees  and  they  are  involved  in
provisioning, construction and cleaning of nests as well as feeding larvae and queen
bee. The worker bees are responsible to search for pollen,  nectar and plant resin.
Pollen, nectar and plant resin can be processed by worker bees to honey, bee bread
and propolis respectively. The foraged items by worker bees will be brought into nest
to be reorganised into nest cavity. Water is collected more in hot environment to cool
the nest cavity and for liquifying honey. Propolis or geopropolis  or cerumen is a
mixture  of  beewax  and  plant-based  resins  with  the  addition  of  processing  by
mandibular secretion to construct comb and lining of nest cavity (Van Veen, 2014;
Wille, 2003). 
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2.3 History of Propolis 
The term “propolis” is derived from ancient Greek writing: pro refers to “in front of”
or  “at  the  entrance  of”  and polis  means  “city”  or  “community”,  in  other  words,
propolis  means substance  for  hive defense.  Indeed,  the  bees  know that  there  are
diseases within their community will spread very fast as their hive is small. Propolis
is their antibiotic, preventing bacteria, virus or parasite to lurk in beehive. It is used
extensively,  from lining  of  internal  layer  of  nest  cavity  and  reparative  works  in
beehive  to  embalming  dead intruders  which  are  too  big  to  be  transported.  Also,
propolis  functions  to  keep  the  beehive  humid  and  cool  (Bankova  et  al.,  2000;
Kuropatnicki et al., 2013; Toreti et al., 2013).
During  ancient  times,  propolis  was  sold  together  with  honey  and  became  a
commodity amongst Greeks, Romans, Persians and Jews due to the strong aroma.
People often used propolis  externally  and consumption.  Since then,  propolis  was
found  to  have  multiple  medicinal  benefit.  Propolis  can  cure  bruises,  wounds,
suppurative  sores,  ulcers,  pain,  tumor,  eczema,  myalgia,  rheumatism.  During
medieval  times,  propolis  disappeared from mainstream medicine.  Fortunately,  the
knowledge of propolis survived in traditional folk medicine and was resurrected in
European regions. Propolis was then called “penicillin” and made its way to herbal
medicine. In 19th century, the modern research era, alcoholic extract of propolis was
established. The development of research was extensive especially in chemistry to
identify chemical composition of propolis (Bankova et al., 2000; Kuropatnicki et al.,
2013). 
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A glamourous name “Dr Propolis” emerged in Demark in 1970 named Dr Karl Lund
Aagaard who is  a Danish biologist.  He spent 20 years in propolis  collection and
research and found even broader benefit of propolis in addition to existing literature.
The  benefit  of  propolis  extends  to  cancer,  urinary  tract  infection,  gout,  sinus
congestion,  influenza,  bronchitis,  gastritis,  ear  diseases,  intestinal  infection,  lung
infection, headache, biliary infection, warts and conjunctivitis  (Kuropatnicki et al.,
2013). Such exhausting list sparks more researches until today. However, most of the
researches  done  were  from honey  bee  propolis.  Stingless  bee  propolis  is  poorly
studied and obviously less data available in the literature as compared to honey bee
propolis (Sanches et al., 2017). 
2.4 Bioactivity and Chemical Composition of Stingless Bee Propolis
Stingless  bee  propolis  exhibits  pharmacological  potential  such  as  antioxidant
antimicrobial,  anticancer,  antiinflammatory  properties  (Sanches  et  al.,  2017).
Stingless bees explore different plants to yield propolis and the plants are located
within their flight range. It is worth nothing that different species will prefer different
plants  for harvesting resin and secretion.  The plants they foraged are still  poorly
understood.  Therefore,  the  phytochemical  compositions  of  propolis  is  largely
influenced by bee species, location, vegetation and seasonal factors  (Aleixo et al.,
2017; Farnesi et al., 2009; Rushdi et al., 2014). When ethanolic extract of propolis
from two main stingless bee species  in Malaysian meliponiculture  are  compared,
Heterotrigona itama propolis contains more chemical constituent than G. thoracica
propolis.  H. itama  propolis consists of phenolic compounds, terpenoids,  saponins,
steroids,  coumarins  and  essential  oils  but  G.  thoracica  propolis  lacks  saponins,
steroids and coumarins (Ismail et al., 2016; Nazir et al., 2018).
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2.4.1 Stingless Bee Propolis as Natural Antioxidant 
The  antioxidant  nature  of  stingless  bee  propolis  can  help  in  preventing  diseases
caused by oxidative stress. The free radical is converted to harmless compound by
both  enzymatic  and  non-enzymatic  antioxidants.  The  presence  of  antioxidant  in
propolis is attributed to phenolic compounds and flavonoids  (Lavinas et al., 2018).
Most utilised laboratory methods to determine antioxidant  property from propolis
extract  is  free  radical  capturing  DPPH (2,2-diphenyl-1-picrylhydrazyl).  H.  itama
propolis showed higher antioxidative activity than G. thoracica propolis using DPPH
scavenging method (Ismail et al., 2016). 
2.4.2 Antimicrobial activity of Stingless Bee Propolis 
Studies  have reported antibacterial,  antiviral  and antifungi  nature of stingless bee
propolis  and  is  a  promising  natural  agent  for  infectious  diseases.  Stingless  bee
propolis possess bacteriostatic and bactericidal action against wide range of Gram
positive  and Gram negative  bacterias.  The bacterias  implicated  are  Pseudomonas
aeruginosa,  Staphylococcus  aureus,  and  methicillin-resistant  S.  aureus (MRSA),
Escherichia coli, Enterococcus faecalis, Proteus mirabilis and Klebsiella pneumonia
(Lavinas et al., 2018). The antibacterial effect of stingless bee propolis was stronger
in Gram positive than Gram negative bacteria. H. itama propolis in Malaysia showed
better  antibacterial  property  than  G. thoracica propolis  in  all  7  types  of  bacteria
tested  such  as  Staphylococcus  aureus,  Bacillus  subtilis,  E. faecalis,  Listeria
monocytogen, Acinetobacter baumannii, Salmonella typhi and E. coli (N. Ibrahim et
al., 2016). 
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Stingless  bee  propolis  can  inhibit  the  growth  of  Candida  albicans at  a  lower
concentration and kill  them at  a higher concentration  (Campos et  al.,  2014). The
bioactive substance giving antifungi effect is unknown. Also, stingless bee propolis
managed to act against herpes simplex virus 1 (HSV-1) in infected cell cultures. The
concentration of virus that was reflected by the number of viral copies significantly
fall by about 98% after treatment. C-glycosylflavones, catechin-3-O-gallate, and 3,4-
dicaffeoylquinic acid are the main phenolic compounds that offer antiviral activity
(Coelho et al., 2015). 
2.4.3 Anticancer and Antiinflammatory Property of Stingless Bee Propolis
The anticancer  activity  of  stingless  bee  propolis  has  been reported.  Some of  the
cancer  cell  studied  are  glioblastoma,  breast  adenocarcinoma,  oral  squamous  cell
carcinoma and osteosarcoma. Stingless bee propolis managed to stop the progression
cancer cells (Sanches et al., 2017). Furthermore, flavonoids in stingless bee propolis
contains antiinflammatory property both in vitro and in vivo by immunomodulation
of inflammatory mediators.  For instance,  induction  of antiinflammatory  cytokines
and inhibition of proinflammatory cytokines (Campos et al., 2015).
2.5 Therapeutic  Potential  of  Stingless  Bee  Propolis  in  Diabetic
Cardiomyopathy
Regarding the bioactivity of stingless bee propolis that exhibited antidiabetic effect,
six studies reported glucose lowering  effect (Ismail et al., 2016; Mahani et al., 2013;
Nna et al., 2018; Usman et al., 2017; Vongsak et al., 2015) and one study advocated
its cardioprotective activity through antiischemic property in myocardial infarction
(Ahmed et al., 2017). Stingless bee propolis from Indonesia managed to lower blood
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glucose in mice with type 1 diabetes mellitus and comparable to insulin after two
weeks of supplementation  (Mahani et al., 2013). Besides, Malaysian stingless bee
propolis  showed antihyperglycaemic effect by increasing plasma insulin,  reducing
plasma glucagon and insulin resistance and restoring degenerated  pancreatic  beta
cells  (Nna et al., 2018; Usman et al., 2017). Synergistic glucose lowering effect of
metformin and Malaysian stingless bee propolis was observed  (Nna et  al.,  2018).
Also,  Malaysian  and  Thailand  stingless  bee  propolis  can  inhibit  α-glucosidase
activity (Ismail et al., 2016; Nna et al., 2018; Vongsak et al., 2015). The hypothesis
of insulin-like action was reported when reduction of blood glucose was observed
after one hour of H. Itama propolis supplementation (Nna et al., 2018). 
In myocardial infarcted rat model, stingless bee propolis was able to reduce oxidative
stress, increase antioxidative enzymes,  improve lipid profile and histopathological
changes in heart tissue  (Ahmed et al., 2017). Whereas diabetic cardiomyopathy is
due to the join action of inflammation and oxidative stress. The antioxidative and
antiinflammatory activity of stingless bee propolis provide a sturdy concept to study
on  the  cardioprotective  effect  of  stingless  bee  propolis  through  the  combined
antioxidative and antihyperglycaemic activity in diabetic rats.
2.6 Experimental Model of Type 1 Diabetes Mellitus
In  1880s,  the  first  animal  model  of  diabetes  was  a  byproduct  of  experimental
pancreatectomy procedure on a dog to study malabsorption of fat in gastrointestinal
system  done  by  Minkowski.  The  animal  developed  overt  clinical  diabetes  with
polyuria, polydipsia and weight loss  (Rees and Alcolado, 2005). In 1920s, Banting
and Macleod named the only dog that survived in their experiment “Marjorie” and
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subsequently involved in the discovery of insulin. This discovery was a huge leap in
physiology and medicine because before that, patients diagnosed with type 1 diabetes
mellitus were only awaiting death. Banting and Macleod were awarded nobel prize
for physiology or medicine in 1923 (Rees and Alcolado, 2005; Vecchio et al., 2018).
Over the years, several animal models were established with the aim getting to the
root of diabetes mellitus. In accordance to the animal ethics principle, animal at the
lowest rank on phylogenic scale should be used (Johnson and Besselsen, 2002). For
instance,  rodents  should  be used to  replace  dogs in  any experimental  procedures
unless there is suitable reason to do otherwise. Besides that, there are a few methods
to induce diabetes mellitus in animal models such as chemical, genetic alterations
and viral induction of diabetes mellitus. Each method has been revised to cater for
different  experiments.  The  advantages  and  disadvantages  of  each  method  are
simplified in the table below.
2.6.1 Methods of Type 1 Diabetes Mellitus Induction in Animal Models
Table 2.1 Methods to induce type 1 diabetes mellitus in Animal models
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varying results, may 
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(von Herrath
et al., 2011; 
von Herrath 
et al., 1997)
2.6.2 Chemical Induction of Type 1 Diabetes Mellitus 
Two most widely used pharmacological agents as chemical for induction of type 1
diabetes mellitus in animal models are alloxan and streptozotocin. Both are glucose
analogues  known to interfere  with  physiological  function  of  pancreatic  beta  cell.
Streptozotocin is preferred over alloxan. The reason being alloxan has a half-life of
1.5 minutes as compared to 15 minutes in streptozotocin, rendering it less suitable in
in  vivo  setting  (Islam  and  Code,  2017;  Szkudelski,  2001).  Also,  streptozotocin-
induced  diabetic  model  has  more  sustained  hyperglycemia  with  clinical  signs  of
diabetes without ketosis, thereby reducing mortality (Islam and Code, 2017). Alloxan
has  more  toxic  effects  to  the  other  organs,  mainly  liver.  Associated  biochemical
changes, morphological and ultrastructural changes are notable in alloxan-induced
diabetes and again increases mortality among study subjects (Lucchesi et al., 2015). 
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2.6.3 Mechanism of Streptozotocin Action
Streptozotocin,  2-deoxy-2-(3-(methyl-3-  nitrosoureido)-D-glucopyranose, is  a
derivative  of  Streptomycetes  achromogenes  and used as  antimicrobial  agent.  The
deoxy group within the chemical structure attached to glucose molecule represents
highly  reactive  deoxyglucose  and  methylnitrosurea  moieties,  acting  as  powerful
cytotoxic  agent  directed  specifically  towards  pancreatic  beta  cells  (Szkudelski,
2001).  Streptozotocin  recognises  glucose  transporter  2  (GLUT  2)  receptors  and
pancreatic  beta  cells  expresses  high amount  of  GLUT 2 in  contrast  to  liver  and
kidney that express lower amount of GLUT 2. Therefore, mild acute kidney and liver
injury is  highly reversible.  For  this  reason, streptozotocin-induced diabetes  offers
good animal model for studying the chronic complications of hyperglycemia in many
organs such as liver, kidney, brain, heart and muscle  (Wu and Yan, 2015). Inside
pancreatic beta cells, streptozotocin’s main mechanism of induction of diabetes is in
DNA  alkylation.  The  transfer  of  methyl  group  from  methylnitrosurea  to  DNA
molecule initiate chain reaction of DNA fragmentation and destruction, leading to
beta cell necrosis and lack of insulin production (Radenkovic et al., 2016). 
2.6.4 Practical Application of Streptozotocin
Single dose with 50-60 mg/kg streptozotocin to induce type 1 diabetes mellitus in
adult male Wistar rats resulted in clinical overt diabetic symptoms. Dosage more and
less  than  the  range  of  dosage  resulted  in  death  and  inadequate  hyperglycemia
respectively.  The mortality  rate  was 12.5-25% due to  the  acute  hypoglycemia  in
within 6-24 hours of induction with streptozotocin. So, glucose solution in the first
day  is  recommended  to  reduce  mortality.  Streptozotocin-induced  type  1  diabetes
mellitus  in  rats  achieved  stable  hyperglycemia  even after  17  weeks  of  induction
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(Gajdosik et al., 1999). Therefore, streptozotocin provides a feasible framework for
studying chronic complications of type 1 diabetes mellitus including heart.
2.6.5 Diabetic Cardiomyopathy in Streptozotocin-induced Diabetic Rat Model
Rodents are useful model in studying diabetic cardiomyopathy due to the resistive
nature to atherosclerosis, effectively rule out coronary heart disease as confounding
factor among study subjects. The first scientist who pioneered the method of using
rodents  in  proving  the  existence  of  diabetic  cardiomyopathy  in  type  1  diabetes
mellitus was Dr. John McNeill.  The comprehensive evidence covered decrease in
contractile  performance  of  working  heart  and  isolated  cardiomyocyte,  associated
biochemical  changes  and  adrenergic  dysregulation  (Severson,  2004).  Multiple
studies  managed  to replicate  the  findings  using type  1  and even type  2 diabetic
rodent  models  (Boudina  and  Abel,  2007).  Four  weeks  after  induction  of  type  1
diabetes mellitus with streptozotocin lead to the features of diabetic cardiomyopathy
such  as  cardiac  hypertrophy,  apoptosis,  fibrosis  and  perivascular  fibrosis  in  rats
(Fiordaliso et al., 2000; Miric et al., 2001). Treatment given within two to four weeks
after induction of type 1 diabetes mellitus can reverse pathological changes in heart
such as cardiac and perivascular fibrosis and manifested as improvement in cardiac
function (Miric et al., 2001).
2.7 Structural and Functional Phenotype in Diabetic Cardiomyopathy
There is no universally accepted definition of diabetic cardiomyopathy due to the
challenges  faced  by  scientists  when  dealing  with  complex  pathophysiology.  The
general  definition  of  diabetic  cardiomyopathy  is  structural  and  functional
abnormalities of myocardium in diabetic patients in the absence of hypertension or
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coronary  artery  disease  (Miki  et  al.,  2013).  Diabetic  cardiomyopathy  includes
structural  abnormalities  such  as  cardiac  hypertrophy,  interstitial  fibrosis  and
perivascular fibrosis and functional changes such as diastolic dysfunction and in late
stage, systolic dysfunction. The most striking feature of diabetic cardiomyopathy is
cardiac fibrosis including cardiac fibrosis and perivascular fibrosis. The histological
changes  such as cardiac  hypertrophy and interstitial  fibrosis  can stiffen the heart
ventricles  and  reduce  compliance.  In  addition,  cross-linking  of  collagen  due  to
uncontrolled hyperglycemia will further impair cardiac elasticity, leading to diastolic
dysfunction. (Sharma and McNeill, 2006). 
2.7.1 Cardiac Hypertrophy
Cardiac hypertrophy is a non-specific phenomenon in reaction to stress. For instance,
cardiac hypertrophy seen in athletes is the initial stage of physiological response to
stress. On the other hand, pathological hypertrophy occurs when cell death, fibrosis,
altered  cardiomyocyte,  mitochondrial  dysfunction  and  inadequate  angiogenesis  in
response  to  stress  (Nakamura  and  Sadoshima,  2018).  There  is  a  link  between
progression of cardiac hypertrophy in diabetes mellitus and heart  failure which is
pathological. This can be attributed to cardiomyocyte hypertrophy, death and loss of
function (Feng et al., 2010; Samak et al., 2016).
2.7.2 Interstitial and Perivascular Fibrosis
The architecture of myocardium is a complex network of tightly and well-arranged
cardiomyocytes  and  extracellular  matrix  protein.  The  main  component  of
extracellular matrix is collagen, with 85% of type 1 collagen offering greatest tensile
strength  and  11%  of  type  III  collagen  giving  elasticity  of  cardiac  tissue.  The
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